Olma.O

Olema Pharmaceuticals maintains a conservative capital structure characterized by zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet reflects total assets of $533.4 million against total liabilities of $54.9 million, yielding total equity of $478.6 million. Liquidity is constrained by a cash and equivalents position of $48.3 million, which stands in contrast to a negative operating cash flow of -$146.7 million. The company trades at a price-to-book ratio of 2.01, implying a market capitalization of $961.9 million based on 81.4 million shares outstanding.

Profitability metrics indicate significant operational losses, with an operating income of -$178.7 million and net income of -$162.5 million. These losses drive a negative return on equity of -33.95% and a negative return on assets of -30.45%. The enterprise value to EBITDA ratio is negative at -5.11, reflecting the absence of positive earnings before interest, taxes, depreciation, and amortization. The company is currently in a pre-profitability phase typical of early-stage pharmaceutical developers.

Segment and geographic revenue mix data are not available in the provided financial snapshot. Consequently, specific revenue concentration risks by product line or region cannot be quantified from the current dataset. The analysis relies on aggregate financial figures rather than disaggregated segment performance.

Growth trajectory analysis is limited by the absence of historical period data in the input. Without multi-year revenue or net income trends, it is not possible to assess the year-over-year growth rate or the consistency of financial performance over time. The current snapshot represents a single point in time without comparative historical context.

Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The primary financial risk stems from the negative operating cash flow, which consumes cash reserves. However, the absence of debt mitigates interest coverage risks. The low dilution rating suggests that recent share issuance has not been aggressive, preserving existing shareholder value from immediate dilution pressures.

Recent observations highlight strong analyst sentiment, with a mean price target of $39.44 and a median target of $40.00, significantly above the current market price of $11.82. The mean recommendation is 1.75, driven by four strong-buy and seven buy ratings, with only one hold. This disparity between market price and analyst targets suggests expectations of future value realization, likely tied to clinical milestones or regulatory approvals not detailed in the financial snapshot.

Operating income −66,3% YoY; Net income −74,7% YoY.

• ▍Operating income −66,3% YoY
• ▍Net income −74,7% YoY
• ▍Free cash flow −75,0% YoY

Operating income −36,2% YoY; Net income −37,2% YoY.

• ▍Operating income −36,2% YoY
• ▍Net income −37,2% YoY
• ▍Free cash flow −37,1% YoY

Operating income −21,9% YoY; Net income −22,2% YoY.

• ▍Operating income −21,9% YoY
• ▍Net income −22,2% YoY
• ▍Free cash flow −22,4% YoY

Operating income −42,8% YoY; Net income −44,1% YoY.

• ▍Operating income −42,8% YoY
• ▍Net income −44,1% YoY
• ▍Free cash flow −44,1% YoY

Operating income -$34.9M.

• ▍Operating income -$34.9M

Operating income -$36.8M.

• ▍Operating income -$36.8M

Operating income -$37.6M.

• ▍Operating income -$37.6M

Operating income -$33.5M.

• ▍Operating income -$33.5M

Operating income −25,6% YoY; Net income −25,5% YoY.

• ▍Operating income −25,6% YoY
• ▍Net income −25,5% YoY
• ▍Free cash flow −25,3% YoY

Operating income −35,5% YoY; Net income −34,0% YoY.

• ▍Operating income −35,5% YoY
• ▍Net income −34,0% YoY
• ▍Free cash flow −34,2% YoY

Operating income +1,9% YoY; Net income +7,8% YoY.

• ▍Operating income +1,9% YoY
• ▍Net income +7,8% YoY
• ▍Free cash flow +8,1% YoY

Operating income −49,6% YoY; Net income −47,4% YoY.

• ▍Operating income −49,6% YoY
• ▍Net income −47,4% YoY
• ▍Free cash flow −44,5% YoY